Vote Scores

Home / Companies / Gilead Sciences, Inc.

Company · votes reported on Form N-PXGILD · SEC company no. 882095

Gilead Sciences, Inc.

How funds and institutional managers reported voting their shares, year to 30 June 2026

Filers reporting
1,771year to 30 June 2026
Against management on pay
6.9%118 of 1,708 reporting filers
Same, by reported shares
4.6%shares reported on Form N-PX
Meetings on file
6across 3 seasons
89.9% for6.8% against3.4% other6.9% against management1,747 filers on say-on-pay

foragainstabstain, withhold or otheramber tick: the portion cast against management

1,771 Form N-PX filers reported votes at Gilead Sciences, Inc. for the year to 30 June 2026, across 4 meetings.

On the advisory vote on executive pay, 118 of the 1,708 filers that reported a position voted against management (6.9%), close to the median company on this site (6.6%). By reported shares the figure is 4.6% (median 2.9%). These are shares of the filers reporting on Form N-PX, not of all votes cast at the meeting.

Meetings

Meeting dateSeasonFilers reportingItemsAgainst management on pay
30 Apr 2026year to 30 June 20261,75886.9%
20 Apr 2026year to 30 June 2026320.0%
6 Mar 2026year to 30 June 20263133.3%
7 May 2025year to 30 June 20251,68698.0%
5 Aug 2024year to 30 June 2024510.0%
8 May 2024year to 30 June 20241,59099.8%

Meetings with 20 or more reporting filers have their own page with every item. Dates are as filers typed them; dates up to three days apart are treated as one meeting.

Say-on-pay: this company and the median

year to 30 June 2026Gilead Sciences, Inc.Median company
Reporting filers voting against management6.9%6.6%
Reported shares voted against management4.6%2.9%

Among filers reporting on Form N-PX. The median is over 3,799 companies with a say-on-pay item reported by 20 or more filers.

How the largest families voted

Meeting of 30 Apr 2026: say-on-pay and each shareholder proposal that could be told apart.

FamilySay-on-payProposal AProposal BProposal C
VanguardForAgainstAgainstAgainst
BlackRock and iSharesForAgainstAgainstAgainst
FidelityForAgainstAgainstAgainst
DimensionalForAgainstAgainstAgainst
State Street and SPDRForAgainstAgainstAgainst
American CenturyForAgainstAgainstAgainst
Franklin TempletonForAgainstAgainstAgainst
InvescoForAgainstAgainstAgainst
EquitableForAgainstAgainstAgainst
Charles SchwabForAgainstAgainstAgainst
Nuveen and TIAAForAgainstAgainstAgainst
ProShares and ProFundsForAgainstAgainstAgainst
John Hancock and ManulifeForAgainstFor *Against
Morgan Stanley, Eaton Vance and CalvertForAgainstAgainstAgainst
J.P. MorganForAgainstAgainstAgainst
Goldman SachsForAgainstAgainstAgainst
WisdomTreeForAgainstAgainstAgainst
PGIM and PrudentialForAgainstFor *For *
Jackson National fundsForAgainstAgainstAgainst
Northern Trust and FlexSharesForAgainstAgainstFor *
SEIForAgainstFor *Against
T. Rowe PriceForAgainstAgainstAgainst
ThriventForAgainstAgainstAgainst
Lincoln FinancialForAgainstAgainstAgainst
VoyaForAgainstAgainstAgainst
First TrustForAgainstAgainstAgainst
Russell InvestmentsForAgainstFor *Against
NationwideForAgainstAgainstAgainst
Victory CapitalForAgainstAgainstAgainst
Brighthouse FundsForAgainst *Against *Against *
Guggenheim and RydexForAgainstAgainstAgainst
Columbia ThreadneedleForAgainstFor *Against
BNY MellonForAgainstAgainstAgainst
PrincipalForAgainstAgainstAgainst
Capital Group and American FundsForAgainstFor *Against
Pacific Life fundsForAgainstAgainstAgainst
Global XForAgainstFor *Against
MFSAgainst *AgainstAgainstAgainst
TransamericaForAgainstAgainstAgainst
Federated HermesForAgainstFor *Against
AllianceBernsteinForAgainstAgainstAgainst
Hartford FundsForAgainstAgainstAgainst
DWSForAgainstAgainstFor *
PIMCOForAgainstAgainstAgainst
AllspringForAgainstAgainstAgainst
MassMutualForAgainstFor *Against
Harbor FundsForAgainstFor *For *
VirtusForAgainstAgainstAgainst
VanEckForAgainstFor *Against
Macquarie and Delaware FundsForAgainstAgainstAgainst
Janus HendersonForAgainstFor *Against
Neuberger BermanForAgainstFor *Against
American BeaconForAgainstNo reportAgainst
Natixis and Loomis SaylesForAgainstFor *Against
Lord AbbettForAgainstAgainstAgainst
Dodge & CoxForAgainstAgainstAgainst
Harris Associates and OakmarkForNo reportNo reportNo report
BairdForNo reportNo reportNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

By season

SeasonFilers reportingAgainst management on pay, filersBy reported sharesSay-on-pay split
year to 30 June 20241,5969.8%withheld
year to 30 June 20251,7058.0%5.7%
year to 30 June 20261,7716.9%4.6%

Category mix

Share of the vote records reported for this company, by the category filers chose.

CategoryVote recordsShare
DIRECTOR ELECTIONS34,28054.7%
SECTION 14A SAY-ON-PAY VOTES9,05814.5%
CORPORATE GOVERNANCE5,1548.2%
AUDIT-RELATED3,8036.1%
OTHER SOCIAL ISSUES3,6865.9%
COMPENSATION2,7984.5%
DIVERSITY, EQUITY, AND INCLUSION2,6404.2%
HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCE1,2011.9%

Questions

How did large funds vote at Gilead Sciences, Inc.?

For the year to 30 June 2026, 1,708 Form N-PX filers reported a say-on-pay vote at Gilead Sciences, Inc.; 118 voted against management (6.9%). The table on this page lists the position of each of the largest fund families on say-on-pay and on each shareholder proposal that could be told apart in the filings.

Were there shareholder proposals at Gilead Sciences, Inc.?

Filers reported 3 proposals from security holders that could be told apart in the year to 30 June 2026. Across them, 8.7% of reporting filers voted for at the median proposal.

Is this the meeting result?

No. The figures are shares of the funds and managers that file Form N-PX, and of the shares they reported. Holders that do not file the form (individuals, most foreign investors, insiders) are not included, so the split here can differ widely from the certified result, which Gilead Sciences, Inc. reports on Form 8-K.

Where does the data come from?

From Form N-PX filings on the SEC's EDGAR system, grouped by company. Filers type company names and meeting dates themselves; this site groups spellings of the same company and folds meeting dates up to three days apart. Data runs through 23 Sep 2026; the median compares 3,799 companies.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Gilead Sciences, Inc., grouped by company. The name is the most common spelling among filers; the ticker and SEC company number come from the SEC company tickers file, matched on the exact name. Not verified by the SEC. Filings read through 23 Sep 2026; page built 26 Sep 2026.